In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xoft Inc.

Division of iCAD Inc.
www.xoftmicrotube.com

Latest From Xoft Inc.

Deals Update

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

Deals Shaping the Medical Industry (01/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

ASBS 2010: Economy, Rise in Mastectomies Temper Minimally Invasive Advancements in Breast Care

Surgeons attending the 11th annual meeting of the American Society of Breast Surgeons were perplexed by the reversal of the trend away from mastectomy and toward breast-conserving therapies. Advanced breast-conserving products were presented at the meeting; but with lowered revenue expectations that can ultimately be attributed to the economic woes of the past couple of years. High unemployment and the lack of health care coverage have prompted many women to delay or forego their yearly mammogram, and as a result, the numbers of biopsies, surgeries, and radiation therapy procedures have declined as well.
Medical Device

Frontiers in Breast Cancer Research, Part II: Developments in Partial Breast Irradiation and Tumor Ablation

As the use of breast conserving lumpectomy expands as a treatment for early-stage breast cancer, interest has surged in alternatives to whole breast irradiation. Follow-on radiation treatment is crucial to the success of this therapy, but a significant number of women are either unable or unwilling to undergo the typical treatment course involving five to seven weeks of daily radiation therapy. The device industry is responding with technologies aimed at delivering post-lumpectomy radiation therapy in a more convenient, potentially safer way.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gynecological, Urological
  • Alias(es)
  • Xoft microTube Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • iCAD Inc.
  • Senior Management
  • Michael Klein, Pres. & CEO
    Robert Kirby, VP, Bus. Dev.
    Robert R Burnside, VP, R&D
    Lisa Baird, VP, Mktg.
    Mhairi Jones, VP, Fin.
  • Contact Info
  • Xoft Inc.
    Phone: (408) 419-2300
    345 Potrero Ave.
    Sunnyvale, CA 94085
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register